Trending NewsTrending NewsNASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $432.80 +2.70 (+0.63%) Closing price 04:00 PM EasternExtended Trading$433.00 +0.20 (+0.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medpace Stock (NASDAQ:MEDP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medpace alerts:Sign Up Key Stats Today's Range$421.52▼$434.8650-Day Range$393.42▼$528.4452-Week Range$287.17▼$628.92Volume233,162 shsAverage Volume414,089 shsMarket Capitalization$12.36 billionP/E Ratio27.20Dividend YieldN/APrice Target$467.08Consensus RatingHold Company Overview Medpace Holdings, Inc. (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market. Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing. By integrating these disciplines under one roof, the company aims to ensure consistency in trial design, execution and data analysis, while maintaining compliance with international regulatory standards. Founded in 1992 by Dr. August J. Troendle and headquartered in Cincinnati, Ohio, Medpace has expanded its footprint to serve clients around the world. The company operates facilities and offices across North America, Europe, the Asia-Pacific region and Latin America, enabling it to manage global studies and facilitate site activation in diverse regulatory environments. Under the leadership of founder and chairman Dr. August J. Troendle, Medpace draws on a multidisciplinary team of scientific, medical and regulatory experts. The company’s management emphasizes close collaboration with sponsors, leveraging therapeutic area specialists and regional capabilities to address the unique challenges of each clinical program and advance patient-focused research.AI Generated. May Contain Errors. Read More Medpace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreMEDP MarketRank™: Medpace scored higher than 61% of companies evaluated by MarketBeat, and ranked 343rd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingHold Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 4 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Medpace is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMedpace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth8.80% Earnings GrowthEarnings for Medpace are expected to grow by 8.80% in the coming year, from $17.04 to $18.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 27.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 27.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.99.Price to Earnings Growth RatioMedpace has a PEG Ratio of 2.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 20.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.83% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 15.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.27 News SentimentMedpace has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Medpace this week, compared to 11 articles on an average week.Search Interest9 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows9 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,436,197.00 in company stock.Percentage Held by Insiders20.50% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MEDP Stock News HeadlinesBronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMay 22 at 12:00 PM | globenewswire.comMedpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 22 at 12:00 PM | prnewswire.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.May 22 at 1:00 AM | Porter & Company (Ad)Cincinnati biopharma firm helmed by Medpace founder makes commercial debutMay 22 at 10:58 AM | bizjournals.comMEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 22 at 10:16 AM | globenewswire.comMEDP Lawsuit Alert: Medpace Investors are Notified of the Ongoing Securities Class Action Over the Company's Potential Misstatements – Contact BFA Law if You Lost MoneyMay 22 at 6:47 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Medpace Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MEDPMay 21 at 3:10 PM | prnewswire.comINVESTOR ALERT: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, RGRD Law Announces - MEDPMay 21 at 3:03 PM | globenewswire.comSee More Headlines MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $561.65 at the beginning of the year. Since then, MEDP stock has decreased by 22.9% and is now trading at $432.80. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its earnings results on Wednesday, April, 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.74 by $0.54. The business's revenue was up 26.5% compared to the same quarter last year. Read the conference call transcript. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's top institutional shareholders include Wasatch Advisors LP (2.71%), Renaissance Technologies LLC (1.77%), Arrowstreet Capital Limited Partnership (1.39%) and Dimensional Fund Advisors LP (1.22%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Jesse J Geiger, Stephen P Ewald, Cornelius P Mccarthy III, Kevin M Brady, Fred B Davenport Jr, Robert O Kraft and Ashley M Keating. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings4/22/2026Today5/22/2026Next Earnings (Estimated)7/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MEDP's financial health is in the Red zone, according to TradeSmith. MEDP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees6,200Year Founded1992Price Target and Rating Average Price Target for Medpace$467.08 High Price Target$582.00 Low Price Target$305.00 Potential Upside/Downside+7.9%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$15.91 Trailing P/E Ratio27.20 Forward P/E Ratio25.40 P/E Growth2.18Net Income$451.12 million Net Margins17.19% Pretax Margin21.35% Return on Equity120.89% Return on Assets24.79% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$2.53 billion Price / Sales4.89 Cash Flow$17.12 per share Price / Cash Flow25.28 Book Value$20.95 per share Price / Book20.66Miscellaneous Outstanding Shares28,560,000Free Float22,705,000Market Cap$12.36 billion OptionableOptionable Beta1.19 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:MEDP) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredThe Most Important Tech Company in America?One private company holds over $26 billion in government contracts tied to AI warfare and defense systems - an...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
